Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2012
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 13 Oct 2011 New trial record